Memantine (DrugBank: Memantine)
7 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
2 | Amyotrophic lateral sclerosis | 6 |
6 | Parkinson disease | 17 |
8 | Huntington disease | 2 |
13 | Multiple sclerosis/Neuromyelitis optica | 8 |
49 | Systemic lupus erythematosus | 2 |
127 | Frontotemporal lobar degeneration | 4 |
205 | Fragile X syndrome related disease | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04302870 (ClinicalTrials.gov) | February 27, 2020 | 4/3/2020 | Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial | Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial | Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Drug: Memantine Hydrochloride Oral Solution;Drug: Trazodone Hydrochloride oral solution;Drug: Placebo oral solution | University of Edinburgh | University College, London;University of Warwick;NHS Lothian | Recruiting | 18 Years | N/A | All | 750 | Phase 2;Phase 3 | United Kingdom |
2 | NCT02118727 (ClinicalTrials.gov) | November 7, 2018 | 15/4/2014 | Therapy in Amyotrophic Lateral Sclerosis (TAME) | Multi-centered Double Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Memantine at 20 mg BID in Patients With ALS | Amyotrophic Lateral Sclerosis;Frontal Temporal Dementia | Drug: Memantine;Drug: Placebo (for Memantine) | University of Kansas Medical Center | NULL | Recruiting | 18 Years | 85 Years | All | 90 | Phase 2 | United States |
3 | EUCTR2007-002117-39-ES (EUCTR) | 31/01/2008 | 12/02/2008 | MEMANTINA (Ebixa X) PARA LA DISCAPACIDAD FUNCIONAL EN LA ESCLEROSIS LATERAL AMIOTRÓFICAMEMANTINE (Ebixa R) FOR FUNCTIONAL DISABILITY IN AMYOTROPHIC LATERAL SCLEROSIS . - MEDALS | MEMANTINA (Ebixa X) PARA LA DISCAPACIDAD FUNCIONAL EN LA ESCLEROSIS LATERAL AMIOTRÓFICAMEMANTINE (Ebixa R) FOR FUNCTIONAL DISABILITY IN AMYOTROPHIC LATERAL SCLEROSIS . - MEDALS | Esclerosis Lateral AmiotroficaAmyotrophic lateral Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis | Trade Name: EBIXA INN or Proposed INN: MEMANTINE HYDROCHLORIDE | Jorge Matias-Guiu Guia | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 140 | Spain | |||
4 | NCT00409721 (ClinicalTrials.gov) | March 2007 | 8/12/2006 | The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS) | A Randomized, Double-blind, Dose Ranging Study to Determine the Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Patients With ALS | Amyotrophic Lateral Sclerosis | Drug: Memantine | University of Alberta | ALS Association | Completed | 18 Years | 80 Years | Both | 42 | Phase 2 | Canada |
5 | NCT00353665 (ClinicalTrials.gov) | July 2005 | 18/7/2006 | Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS) | Phase 2-3 - Memantine for Disability in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Memantine (Ebixa);Drug: riluzole;Drug: Placebo | University of Lisbon | H. Lundbeck A/S | Completed | 20 Years | 75 Years | Both | 63 | Phase 2;Phase 3 | Portugal |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | NCT01020331 (ClinicalTrials.gov) | June 2005 | 20/11/2009 | Memantine Therapy in Amyotrophic Lateral Sclerosis | Phase IIA Open Label Trial of Memantine in Combination With Riluzole (Customary Care) for the Treatment of ALS | Amyotrophic Lateral Sclerosis | Drug: Memantine | Phoenix Neurological Associates, LTD | Forest Laboratories | Completed | 18 Years | 85 Years | Both | 20 | Phase 2 | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04117178 (ClinicalTrials.gov) | February 4, 2020 | 30/9/2019 | Monitoring Anti-Dementia Drugs by Serum Levels | Monitoring Anti-Dementia Drugs by Serum Levels: Importance of Serum Levels, Drug-monitoring, Side-effects, Clinical Efficacy and Compliance (Translation of Official Danish Title) | Dementia;Dementia With Lewy Bodies;Dementia in Parkinsons Disease;Dementia Alzheimers;Alzheimer Disease | Drug: Donepezil;Drug: Memantine;Diagnostic Test: Measurement of serum level of anti-dementia drug | Zealand University Hospital | Epilepsihospitalet Filadelfia | Recruiting | 18 Years | N/A | All | 110 | Phase 4 | Denmark |
2 | NCT03858270 (ClinicalTrials.gov) | April 1, 2019 | 2/10/2018 | Inhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine | Inhibition of a-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine | Parkinson Disease | Drug: Memantine;Other: Placebo | Wayne State University | NULL | Recruiting | 45 Years | 85 Years | All | 50 | Phase 3 | United States |
3 | EUCTR2017-002707-10-DK (EUCTR) | 10/04/2018 | 03/11/2017 | Measurements of drug concentration in the blood for anti-dementia drugs, in order to improve efficacy and reduce side-effects | Serum-monitoring of anti-dementia drugs, and the relevance to side-effects, clinical efficacy and compliance | Dementia in Alzheimers Disease, Parkinsons Disease and Dementia with Lewy Bodies MedDRA version: 20.0;Level: PT;Classification code 10012271;Term: Dementia Alzheimer's type;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease;Classification code 10067889;Term: Dementia with Lewy bodies;Classification code 10075174;Term: Mixed dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Memantin Orion INN or Proposed INN: MEMANTINE Product Name: Donepezil Sandoz Product Code: 25330 INN or Proposed INN: DONEPEZIL | Regional Dementia Research Centre, Dept of Neurology | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 110 | Phase 4 | Denmark | ||
4 | JPRN-UMIN000010596 | 2013/05/01 | 01/05/2013 | Randomized crossover trial comparing memantine or amantadine for Parkinson's disease with motor fluctuations in Juntendo | Parkinson's disease | Memantine preceding arm Titrate the memantine, administered for 3 months. And tapering memantine and amantadine titrate the dose for 3 months. Amantadine preceding arm Titrate the amantadine, administered for 3 months. And tapering amantadine and memantine titrate the dose for 3 months. | Department of Neurology, Juntendo University School of Medicine | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male | 40 | Not selected | Japan | |
5 | NCT01108029 (ClinicalTrials.gov) | October 2009 | 20/7/2009 | Study of Memantine for Gait Disorders And Attention Deficit In Parkinson's Disease | Study of Memantine to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Monocentric Trial | Parkinson's Disease;Gait Disorders, Neurologic | Drug: memantine;Drug: placebo | University Hospital, Lille | NULL | Completed | 30 Years | 80 Years | Both | 28 | Phase 4 | France |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | EUCTR2005-002038-36-GR (EUCTR) | 27/02/2007 | 09/10/2006 | A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies | A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies | Patients with Parkinson’s disease dementia or dementia with Lewy Bodies MedDRA version: 8.1;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease | Trade Name: Ebixa Product Name: Ebixa INN or Proposed INN: MEMANTINE HYDROCHLORIDE Trade Name: Ebixa Product Name: Ebixa INN or Proposed INN: MEMANTINE HYDROCHLORIDE Trade Name: Ebixa Product Name: Ebixa INN or Proposed INN: MEMANTINE HYDROCHLORIDE Trade Name: Ebixa Product Name: Ebixa INN or Proposed INN: MEMANTINE HYDROCHLORIDE | H. Lundbeck A/S | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 200 | Germany;United Kingdom;France;Spain;Italy;Greece;Austria | |||
7 | NCT00855686 (ClinicalTrials.gov) | January 2007 | 3/3/2009 | Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies | A Randomised, Double-blind, Placebo-controlled, 6-month Study of the Efficacy and Safety of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies | Parkinson's Disease Dementia;Dementia With Lewy Bodies | Drug: Memantine;Drug: Placebo | H. Lundbeck A/S | NULL | Completed | 50 Years | N/A | Both | 199 | Phase 4 | Germany |
8 | EUCTR2005-002038-36-FR (EUCTR) | 01/12/2006 | 24/08/2010 | A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies | A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies | Patients with Parkinson’s disease dementia or dementia with Lewy Bodies | Trade Name: Ebixa Product Name: Ebixa INN or Proposed INN: MEMANTINE HYDROCHLORIDE Trade Name: Ebixa Product Name: Ebixa INN or Proposed INN: MEMANTINE HYDROCHLORIDE Trade Name: Ebixa Product Name: Ebixa INN or Proposed INN: MEMANTINE HYDROCHLORIDE Trade Name: Ebixa Product Name: Ebixa INN or Proposed INN: MEMANTINE HYDROCHLORIDE Trade Name: Ebixa Product Name: Ebixa INN or Proposed INN: MEMANTINE HYDROCHLORIDE Trade Name: Ebixa Product Name: Ebixa INN or Proposed INN: MEMANTINE HYDROCHLORIDE | H. Lundbeck A/S | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 200 | Germany;United Kingdom;France;Spain;Italy;Greece;Austria | |||
9 | EUCTR2005-002038-36-DE (EUCTR) | 29/11/2006 | 19/01/2007 | A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies | A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies | Patients with Parkinson’s disease dementia or dementia with Lewy Bodies | Trade Name: Ebixa Product Name: Memantine INN or Proposed INN: MEMANTINE HYDROCHLORIDE Product Name: Memantine INN or Proposed INN: MEMANTINE HYDROCHLORIDE Trade Name: Ebixa Product Name: Memantine INN or Proposed INN: MEMANTINE HYDROCHLORIDE Product Name: Memantine INN or Proposed INN: MEMANTINE HYDROCHLORIDE | H. Lundbeck A/S | NULL | Not Recruiting | Female: yes Male: yes | 200 | United Kingdom;Germany;France;Spain;Italy;Greece;Austria | |||
10 | EUCTR2005-002038-36-GB (EUCTR) | 31/10/2006 | 09/10/2006 | A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies | A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies | Patients with Parkinson’s disease dementia or dementia with Lewy Bodies MedDRA version: 8.1;Level: LLT;Classification code 10012284;Term: Dementia due to Parkinson's disease | H. Lundbeck A/S | NULL | Not Recruiting | Female: yes Male: yes | 200 | Phase 4 | France;Greece;Spain;Austria;Germany;Italy;United Kingdom | |||
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
11 | EUCTR2005-002038-36-AT (EUCTR) | 22/09/2006 | 09/10/2006 | A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies | A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy Bodies | Patients with Parkinson’s disease dementia or dementia with Lewy Bodies | Trade Name: Ebixa Product Name: Ebixa INN or Proposed INN: MEMANTINE HYDROCHLORIDE Trade Name: Ebixa Product Name: Ebixa INN or Proposed INN: MEMANTINE HYDROCHLORIDE Trade Name: Ebixa Product Name: Ebixa INN or Proposed INN: MEMANTINE HYDROCHLORIDE Trade Name: Ebixa Product Name: Ebixa INN or Proposed INN: MEMANTINE HYDROCHLORIDE | H. Lundbeck A/S | NULL | Not Recruiting | Female: yes Male: yes | 200 | Germany;United Kingdom;France;Spain;Italy;Greece;Austria | |||
12 | NCT00294554 (ClinicalTrials.gov) | April 2006 | 21/2/2006 | Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia | Double-Blind Placebo-Controlled Trial of Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia | Parkinson's Disease;Cognitive Impairment;Dementia | Drug: Memantine;Drug: Placebo Oral Tablet | Johns Hopkins University | Forest Laboratories | Completed | 50 Years | N/A | All | 20 | N/A | United States |
13 | NCT00646204 (ClinicalTrials.gov) | April 2006 | 28/12/2007 | Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease | A 16 WEEK, INVESTIGATOR-INITIATED, SINGLE-CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF NAMENDA® (MEMANTINE HCL) FOR NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE | Parkinson's Disease | Drug: Memantine;Drug: placebo | Baylor College of Medicine | Forest Laboratories | Completed | 18 Years | 80 Years | Both | 40 | Phase 4 | United States |
14 | EUCTR2005-004109-27-SE (EUCTR) | 24/03/2006 | 24/01/2006 | A double-blind, placebo-controlled multi-centre trial of memantine in patients with Parkinsons’ disease dementia or dementia with Lewy bodies - MEMDLBPDD | A double-blind, placebo-controlled multi-centre trial of memantine in patients with Parkinsons’ disease dementia or dementia with Lewy bodies - MEMDLBPDD | Parkinsons disease (PD)and dementia with Lewy bodies (DLB) are both common disease of the elderly. The majority of patients who survive for more than 10 years with PD eventually develope dementia (PDD). The brain changes and clinical presentations of PDD and DLB are similar. The clinical characteristics are cognitive impairment with pronounced visuospatial and executive impairment, visual hallucinations, parkinsonism, fluctuations in cognition and REM sleep disorder. | Trade Name: Ebixa Product Name: Ebixa | Neuropsychiatric clinic | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Sweden | |||
15 | NCT00630500 (ClinicalTrials.gov) | February 2006 | 27/2/2008 | Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB) | A Double-blind, Placebo-controlled Multicentre Trial of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies | Dementia Associated With Parkinson's Disease;Dementia With Lewy Bodies | Drug: Memantine;Drug: Placebo | Helse Stavanger HF | King's College London;Lund University | Completed | N/A | N/A | Both | 75 | Phase 2 | Norway;Sweden;United Kingdom |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
16 | EUCTR2004-004139-74-DK (EUCTR) | 20/04/2005 | 22/03/2005 | Parkinson’s Disease: PET scan and evaluation of memantines pharmacological effect.(Parkinsons sygdom bedømt med PET skanning, herunder memantins farmakologiske effekt.) - N/A | Parkinson’s Disease: PET scan and evaluation of memantines pharmacological effect.(Parkinsons sygdom bedømt med PET skanning, herunder memantins farmakologiske effekt.) - N/A | Parkinson's Disease | Trade Name: Ebixa Product Name: Ebixa INN or Proposed INN: memantine | Neurologisk afdeling F | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 12 | Phase 2 | Denmark | ||
17 | NCT00375778 (ClinicalTrials.gov) | April 2005 | 12/9/2006 | Parkinson's Disease Evaluated by PET and the Effect of Memantine | Parkinson's Disease Evaluated by Positron Emission Tomography and the Effect of the NMDA Receptor Antagonist Memantine | Parkinson's Disease | Drug: memantine (drug) | University of Aarhus | Lundbeck Foundation | Completed | 50 Years | 70 Years | Both | 12 | N/A | Denmark |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01458470 (ClinicalTrials.gov) | September 2011 | 20/10/2011 | A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease | A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease; a Phase IIb Study | Huntington Disease | Drug: Memantine;Other: Placebo | University of British Columbia | Huntington Society of Canada;Huntington Study Group | Completed | 18 Years | 75 Years | All | 19 | Phase 2 | Canada |
2 | NCT00652457 (ClinicalTrials.gov) | November 23, 2004 | 31/3/2008 | Study of Memantine to Treat Huntington's Disease | A Pilot Study of Memantine for Cognitive and Behavioral Dysfunction in Huntington's Disease | Huntington's Disease | Drug: Memantine | Jody Corey-Bloom, MD, PhD | Forest Laboratories | Completed | 18 Years | N/A | All | 60 | Phase 4 | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2014-005548-17-FR (EUCTR) | 28/04/2015 | 03/06/2015 | TREATMENT OF PENDULAR NYSTAGMUS WITH GABAPENTIN AND MEMANTINE IN PATIENTS WITH MULTIPLE SCLEROSIS or OCULOPALATAL TREMOR:A CONTROLED OPEN-LABEL STUDY | TREATMENT OF PENDULAR NYSTAGMUS WITH GABAPENTIN AND MEMANTINE IN PATIENTS WITH MULTIPLE SCLEROSIS or OCULOPALATAL TREMOR:A CONTROLED OPEN-LABEL STUDY | PENDULAR NYSTAGMUS IN PATIENTS WITH MULTIPLE SCLEROSIS OR OCULOPALATAL TREMOR MedDRA version: 18.0;Level: PT;Classification code 10029864;Term: Nystagmus;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: NEURONTIN Product Name: Gabapentine Product Code: N03AX12 Other descriptive name: GABAPENTIN Trade Name: EBIXA Product Name: MEMANTINE Product Code: N06DX01 INN or Proposed INN: MEMANTINE | HOSPICES CIVILS DE LYON | NULL | Not Recruiting | Female: yes Male: yes | Phase 2 | France | |||
2 | NCT01744444 (ClinicalTrials.gov) | November 2012 | 30/11/2012 | Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis | Pendular Nystagmus Patients With Multiple Sclerosis | Drug: Memantine;Drug: Gabapentin | Hospices Civils de Lyon | NULL | Completed | 18 Years | N/A | Both | 10 | Phase 2 | France | |
3 | EUCTR2008-000490-37-IT (EUCTR) | 26/02/2008 | 20/03/2008 | Pharmacological treatment with memantine of oscilloscopy in patients suffering from multiple sclerosis: randomized,double blind placebo controlled study. - ND | Pharmacological treatment with memantine of oscilloscopy in patients suffering from multiple sclerosis: randomized,double blind placebo controlled study. - ND | multiple sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10028053;Term: MS | Trade Name: EBIXA INN or Proposed INN: Memantine | OSPEDALE S. RAFFAELE | NULL | Not Recruiting | Female: yes Male: yes | Italy | ||||
4 | NCT00638833 (ClinicalTrials.gov) | September 2007 | 12/3/2008 | Memantine Therapy for Multiple Sclerosis | Pilot Clinical Trial With Memantine for Cognitive Deficits in Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: Memantine;Drug: Placebo | Clinica Universidad de Navarra, Universidad de Navarra | H. Lundbeck A/S | Terminated | 18 Years | 65 Years | Both | 20 | Phase 2 | Spain |
5 | EUCTR2007-000503-15-IT (EUCTR) | 19/02/2007 | 20/04/2007 | Experimental clinical open study, randomized, experimental group vs control group, for the evaluation of tolerability and the effects on magnetic resonance parameters and cognitive functions of memantine in patients at early stage of relapsing- remitting multiple sclerosis treated with interferon-beta. - NEMESI-MS Neuroprotection by Memantine at Early Stage In Multiple Sclerosis | Experimental clinical open study, randomized, experimental group vs control group, for the evaluation of tolerability and the effects on magnetic resonance parameters and cognitive functions of memantine in patients at early stage of relapsing- remitting multiple sclerosis treated with interferon-beta. - NEMESI-MS Neuroprotection by Memantine at Early Stage In Multiple Sclerosis | patients at early stage of relapsing- remitting multiple sclerosis treated with interferon-beta. MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple sclerosis | Trade Name: EBIXA INN or Proposed INN: Memantine | AZ. OSPEDALIERA GARIBALDI, S.LUIGI CURRO , ASCOLI TOMASELLI | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy | ||||
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | NCT00638027 (ClinicalTrials.gov) | July 2006 | 10/3/2008 | Memantine for Spasticity in MS Patients | Memantine for Spasticity in MS Patients | Multiple Sclerosis | Drug: placebo;Drug: memantine | University of Rochester | Forest Laboratories | Completed | 18 Years | 70 Years | All | 21 | Phase 4 | United States |
7 | NCT01074619 (ClinicalTrials.gov) | September 2005 | 12/9/2005 | Study on Cognitive Disorders of Multiple Sclerosis | Effects of Memantine on Cognitive Disorders of Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis | Drug: Memantine;Drug: Placebo | University Hospital, Caen | Ministry of Health, France;H. Lundbeck A/S | Completed | 18 Years | 60 Years | Both | 90 | Phase 3 | France |
8 | NCT00300716 (ClinicalTrials.gov) | April 2004 | 8/3/2006 | Trial of Memantine for Cognitive Impairment in Multiple Sclerosis | Double Blind Placebo Controlled Pilot Trial of Memantine for Cognitive Impairment in Multiple Sclerosis | Multiple Sclerosis;Cognition Disorders | Drug: Memantine | Oregon Health and Science University | Forest Laboratories;University of Southern California;University of Texas Southwestern Medical Center;MS-Hub Seattle | Completed | 18 Years | 65 Years | All | 82 | Phase 2;Phase 3 | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03527472 (ClinicalTrials.gov) | August 23, 2018 | 3/5/2018 | Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus | A Randomized Placebo-controlled, Double Blind Phase 2 Clinical Trial of Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic | Drug: Memantine;Drug: Placebo | Vanderbilt University Medical Center | Kleberg Foundation | Active, not recruiting | 18 Years | 60 Years | All | 46 | Phase 2 | United States |
2 | NCT00181298 (ClinicalTrials.gov) | March 2006 | 13/9/2005 | Memantine in Systemic Lupus Erythematosus | Memantine in Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Drug: Memantine;Drug: Placebo | Johns Hopkins University | Forest Laboratories | Completed | 18 Years | N/A | Both | 61 | N/A | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00545974 (ClinicalTrials.gov) | October 2007 | 16/10/2007 | Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia | A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia | Frontal Lobe Dementia;Frontotemporal Lobe Dementia;Semantic Dementia | Drug: memantine;Drug: Placebo pill | University of California, San Francisco | Forest Laboratories | Completed | 40 Years | 80 Years | All | 81 | Phase 4 | United States |
2 | NCT00594737 (ClinicalTrials.gov) | October 2007 | 7/1/2008 | Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia | An Open Label Pilot Study of the Effects of Memantine Administration on FDG-PET in Frontotemporal Dementia | Frontotemporal Dementia | Drug: memantine hydrochloride | Tiffany Chow, MD | H. Lundbeck A/S | Completed | 40 Years | 80 Years | Both | 17 | Phase 3 | Canada |
3 | NCT00200538 (ClinicalTrials.gov) | September 2005 | 12/9/2005 | Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients | Double-blind, Parallel Group, Placebo-controlled Trial of the Efficacy and Tolerability of Memantine (20 mg) in Frontotemporal Dementia (FTD) Patients | Dementia | Drug: memantine | Nantes University Hospital | NULL | Completed | 45 Years | 75 Years | Both | 52 | Phase 2 | France |
4 | NCT00187525 (ClinicalTrials.gov) | May 2004 | 13/9/2005 | A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration | Frontotemporal Lobar Degeneration | Drug: Memantine | University of California, San Francisco | Forest Laboratories | Completed | 40 Years | 80 Years | Both | Phase 4 | NULL |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00584948 (ClinicalTrials.gov) | September 2007 | 22/12/2007 | Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome | Characterization and Treatment of CNS Abnormalities in Premutation Carriers: A Double-Blind Placebo-Controlled Trial of Memantine | Fragile X-Associated Tremor/Ataxia Syndrome;Fragile X Premutation Carriers | Drug: Memantine;Drug: Placebo | University of California, Davis | National Institute on Aging (NIA);Forest Laboratories | Completed | 30 Years | 80 Years | All | 94 | N/A | United States |